Results 171 to 180 of about 27,778 (225)

Interferon alfa-2b in the management of recurrent conjunctival papillomatosis.

Indian J Ophthalmol, 2016
Singh M, Gautam N, Gupta A, Kaur M.
europepmc   +1 more source

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b. [PDF]

Ther Adv Hematol
Yoon SY, Yoon SS, Yang DH, Lee GW, Sohn SK, Shin HJ, Bae SH, Choi CW, Choi EJ, Cheong JW, Bang SM, Park JS, Park Y, Park YH, Lee SE.   +14 more
europepmc   +1 more source

Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis. [PDF]

Ann Hematol
Nada EA, Elfagieh MA, Abdelsalam F, Elrashedy AA, Idres FA, Shata A, Othman AM, Hamoud HMM, Awadalla RM, Qutob IA, Hamed BM.   +10 more
europepmc   +1 more source

Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways. [PDF]

Blood Adv
Barbui T, Scandura JM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interferon Alfa for Macular Degeneration

Annals of Pharmacotherapy, 1996
Clinical studies demonstrate that interferon alfa has little benefit in treating CNV secondary to macular degeneration. However, it may be useful in the treatment of choroidal and retinal hemangiomas, diabetic and post-vein occlusion retinopathy, and retinopathy of prematurity.
S L, Williford, T, King
openaire   +2 more sources

Scleromyxedema: Treatment with interferon alfa

Journal of the American Academy of Dermatology, 1999
Scleromyxedema is a variant of papular mucinosis characterized by fibroblast proliferation and mucin deposition in the dermis. Historically, it has been very difficult to treat and can cause significant morbidity and mortality with systemic involvement.
J A, Tschen, J R, Chang
openaire   +2 more sources

Interferon-alfa for chronic myeloid leukemia

Seminars in Hematology, 2003
Interferon-alfa (IFNalpha) became the first-line agent for the treatment of chronic myeloid leukemia (CML) because it prolongs survival significantly compared to conventional chemotherapy (CHT). Responses to IFNalpha and the benefits from achieving a response are greater in low-risk than in high-risk patients.
Baccarani, Michele, Russo, Domenico, Rosti, Gianantonio, Martinelli, Giovanni   +3 more
openaire   +3 more sources

Interferon alfa-2a.

British journal of hospital medicine, 1997
Interferon alfa-2a shows both antiviral and antitumoral activity, but its role in the treatment of many conditions remains controversial. It is, however, the treatment of choice for chronic, active hepatitis B, chronic hepatitis C and AIDS-related Kaposi's sarcoma, and is also effective in metastatic renal carcinoma and chronic myelogenous leukaemia ...
C D, Williams, D C, Linch
openaire   +1 more source